Cognition Therapeutics
CGTX
47 hedge funds and large institutions have $12.9M invested in Cognition Therapeutics in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 5 closing their positions.
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
27% more funds holding
Funds holding: 37 → 47 (+10)
2% less capital invested
Capital invested by funds: $13.2M → $12.9M (-$330K)
5.34% less ownership
Funds ownership: 23.52% → 18.18% (-5.3%)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
+$1.34M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.03M |
| 3 |
TIM
Timelo Investment Management
Aurora,
Ontario, Canada
|
+$993K |
| 4 |
CCM
Corsair Capital Management
New York
|
+$588K |
| 5 |
HWM
Hohimer Wealth Management
Seattle,
Washington
|
+$465K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pathstone Holdings
Englewood,
New Jersey
|
-$4.08M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$941K |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$292K |
| 4 |
Mercer Global Advisors
Denver,
Colorado
|
-$122K |
| 5 |
CC
Carlson Capital
Dallas,
Texas
|
-$49.6K |
CGTX Hedge Fund Activity: Q1 2024 in Review
47 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q1 2024, worth a combined $12.9M — down 2.5% from $13.2M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CGTX positions and 5 closed out — a net gain of 10 holders — while 9 added to existing stakes and 10 trimmed.
The largest buyer was AWM Investment Company, opening a new position worth an estimated $1.34M. The largest seller was Pathstone Holdings, exiting entirely with an estimated $4.08M sold.
- 47 institutional investors held Cognition Therapeutics (CGTX) as of Q1 2024, up from 37 in Q4 2023.
- Funds reported $12.9M of Cognition Therapeutics stock for Q1 2024, down 2.5% quarter-over-quarter.
- 15 funds opened new Cognition Therapeutics positions in Q1 2024 and 5 closed out, a net change of +10 holders.
- The largest Cognition Therapeutics buyer in Q1 2024 was AWM Investment Company, an estimated $1.34M added.
- The largest Cognition Therapeutics seller in Q1 2024 was Pathstone Holdings, an estimated $4.08M sold.
Based on aggregated 13F filings for Q1 2024.